Nuvalent IncNASDAQ NUVL Stock Report

Nuvalent, Inc. is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company is advancing a pipeline of product candidates with parallel programs in cancers driven by genomic alterations in the ROS proto-oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), along with multiple discovery-stage research programs. Its lead product candidate, NVL-520, is a ROS1-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases. The Company’s product candidate also includes NVL-655, which is a brain-penetrant ALK-selective inhibitor that is designed to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first, second and third-generation ALK inhibitors.